{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:09:35Z","timestamp":1787501375246,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01000","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:31:30Z","timestamp":1590021090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome"],"prefix":"10.3389","volume":"11","author":[{"given":"Daniel C.","family":"Julien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Woolgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"B1","article-title":"Mucopolysaccharidosis Type II. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, and Amemiya A, editors","volume-title":"GeneReviews is a Registered Trademark of the University of Washington, Seattle. All Rights Reserved","author":"Scarpa","year":"1993"},{"key":"B2","doi-asserted-by":"publisher","first-page":"471325","DOI":"10.1155\/2012\/471325","article-title":"Glycosaminoglycan storage disorders: a review","volume":"2012","author":"Coutinho","year":"2012","journal-title":"Biochem Res Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10545-011-9280-1","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points","volume":"34","author":"Glamuzina","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymgme.2017.06.001","article-title":"Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report","volume":"122","author":"Kim","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36667","article-title":"Mucopolysaccharidosis type II in a female patient with a reciprocal X;9 translocation and skewed X chromosome inactivation","author":"Lonardo","year":"2014","journal-title":"Am J Med Genet A"},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"Pinto","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/gim.2017.30","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review","volume":"19","author":"Bradley","year":"2017","journal-title":"Genet Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the hunter outcome survey (HOS): insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","article-title":"Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/bmt.2009.290","article-title":"Umbilical cord blood transplantation for non-malignant diseases","volume":"44","author":"Prasad","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pcl.2009.11.004","article-title":"Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders","volume":"57","author":"Boelens","year":"2010","journal-title":"Pediatr Clin North Am"},{"key":"B17","first-page":"487","article-title":"Hunter syndrome (mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation","volume":"65","author":"Annibali","year":"2013","journal-title":"Minerva Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with hunter syndrome: outcome after 7 to 17 years","volume":"154","author":"Guffon","year":"2009","journal-title":"J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J Inherit Metab Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol Genet Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s10038-019-0662-9","article-title":"Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future","volume":"64","author":"Chen","year":"2019","journal-title":"J Hum Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2012","journal-title":"Mol Genet Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ymgmr.2017.01.014","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00109-008-0309-3","article-title":"Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease","volume":"86","author":"Matzner","year":"2008","journal-title":"J Mol Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgmr.2014.11.007","article-title":"Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II","volume":"2","author":"Kim","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol Genet Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS ON0E"},{"key":"B33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ymgmr.2015.05.004","article-title":"Immune tolerance strategies in siblings with infantile pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol Genet Metab Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:31:33Z","timestamp":1590021093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2020.01000"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01000","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"article-number":"1000"}}